HIV-1 Subtype-specific Drug Resistance in Patients Failing Dolutegravir (DTG) Based Regimen

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This study looked at patients who experienced virologic failure on a dolutegravir-based regimen — given that I'm currently on or considering a DTG-based regimen, can you tell me what signs of virologic failure I should watch for and how often my viral load should be monitored?
2. 2The trial specifically examined integrase drug resistance mutations that develop when DTG stops working — if I were ever to fail a DTG-based regimen, what second-line treatment options would still be available to me, and how would resistance testing guide that decision?
3. 3Since this was an observational study measuring how quickly virologic failure occurred and how many resistance mutations patients developed, has the research changed how you approach monitoring patients on DTG, and would that affect my care plan?
4. 4The study looked at HIV-1 subtypes and whether they influence which resistance mutations develop — do you know which HIV-1 subtype I have, and does that affect how likely DTG is to remain effective for me long-term?
5. 5This trial has already been completed, so its findings may now be available — are there published results I could review with you to better understand the real-world risk of developing integrase resistance on a dolutegravir regimen?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.